legislation Page 12

Keyword: legislation

215 results found
U.S. push to further regulate ESG products in CAPs could hurt members

The U.S. Department of Labor is taking jabs at the inclusion of environmental, social and governance products in capital accumulation plans — and it could be to members’ detriment. In late June, the Department of Labor proposed new rules around ESG products in retirement accounts. “The proposal is designed, in part, to make clear that . […]

  • By: Staff
  • August 28, 2020 November 30, 2020
  • 09:00
CFA Institute proposing industry standards for ESG disclosure

The CFA Institute is calling out the lack of clarity and standardization around environmental, social and governance investment products. In a consultation paper, the organization proposed its own set of standards, welcoming industry stakeholders to weigh in. As interest in ESG products continues to grow from both retail and institutional investors, confusion remains about the […]

  • By: Staff
  • August 24, 2020 November 30, 2020
  • 08:45

Quebec is applying new pension relief measures and is also extending the credit on employer contributions to the health services fund. The pension relief measures, which the federal government announced in early July, will allow registered pension plans to borrow money and extend the deadline to retroactively credit pensionable service under a defined benefit plan. […]

  • By: Staff
  • August 19, 2020 November 30, 2020
  • 15:15

For defined contribution plan members who were intending to retire in the first half of 2020, the market crash caused by the coronavirus may have upended those plans. Markets reached a trough in March, followed by some recovery, but with little clarity on what investments will do next, it’s a challenging time for plan members […]

Return some excess drug revenues to employers, CLHIA says in submission to PMPRB

In its submission to the Patented Medicine Prices Review Board’s draft guidelines, the Canadian Life and Health Insurance Association is suggesting that the board consider disbursing excess revenues from pharmaceutical companies to employers rather than just to the provincial and territorial public payers. Currently, any excess revenues — determined by voluntary compliance undertaking or orders […]

  • By: Staff
  • August 10, 2020 November 30, 2020
  • 09:30
Trudeau says feds will create EI like benefit for gig, contract workers

Prime Minister Justin Trudeau says the government plans to move out-of-work Canadians into the employment insurance system and provide parallel support for millions set to exhaust emergency pandemic aid who don’t have EI to fall back on. The $80-billion Canada Emergency Response Benefit is set to wind down over the coming weeks, with those who […]

The federal government is easing eligibility rules for the government’s emergency wage subsidy and changing the amounts businesses can receive. The government had been under pressure to make the subsidy more accessible, specifically by loosening the requirement of a 30 per cent drop in revenues, so more companies under that cut-off can qualify. Speaking in Toronto […]

PMPRB changes within scope of Patent Act, rules federal court in judicial review

The Federal Court has upheld reforms to the Patented Medicines Pricing Review Board that updated the board’s reference countries for drug pricing and required it to review three new economic factors when determining whether patented medicines are excessively priced. The court ruled against an argument by Innovative Medicines Canada and 16 pharmaceutical companies in their […]

Benefits plan members, sponsors cite low levels of knowledge on pharmacare: survey

While 67 per cent of Canadian plan members described their level of knowledge about a possible national pharmacare program as low or medium, 27 per cent said they don’t know anything at all about it, according to the 2020 Sanofi Canada health-care survey. Among plan sponsor respondents, 73 per cent described their level of knowledge […]

  • By: Staff
  • June 30, 2020 November 11, 2020
  • 09:15

As reported earlier this month, the Patented Medicine Prices Review Board has published a new draft of its guidelines and launched a 30-day written consultation period. While the law and regulations have already been passed, the implementation has been delayed from July 1, 2020 to Jan. 1, 2021. The new draft guidelines are in response […]